Syngene shares jump 10% after Q4 results; check Macquarie price target

Revenue continues to be impacted by lower business from a single large molecule biologics client. Excluding this, the underlying business showed steady momentum.

Leave a Reply

Your email address will not be published. Required fields are marked *